Category: Professional Posters
Purpose: Lenalidomide(LD) inhibits angiogenesis and shows immunosuppressive effects. LD was introduced to treat multiple myeloma and is known to show positive differences in side effects compared to Thalidomide(TD). In particular, peripheral neuropathy, one of the most common complications of TD in treating the patients with multiple myeloma, was reported less frequent when treating with LD. However, no local study has been conducted to compare the effects of TD and LD in peripheral neuropathy. Therefore, this study was conducted to investigate the appearance, aggravation or improvement of peripheral neuropathy and relevant risk factors in the patients treated with LD and TD.
Methods: The electronic medical records of 169 patients with multiple myeloma who had treated with LD and TD in a tertiary hospital between March 2014 and March 2015 were retrospectively reviewed. The basic characteristics of the patients, the incidence of peripheral neuropathy, and other adverse events were evaluated with the use of a Chi-square test. Logistic regression analysis was used to analyze the risk factors of peripheral neuropathy.
Results: There were 85 patients in the LD group and 84 patients in the TD group for final analysis. The mean age of patients was 62 and 75 years old in the LD and TD group, respectively. There was no significant difference in the presence of diabetes, renal or hepatic functions of patients between the groups. The percentage of patients who showed increased severity of peripheral neuropathy after the treatment was 2.35% in the LD group and 19.05% in the TD group (p<0.001). Six patients in the TD group showed two or greater increase in the grade. A 51.76% in the LD group and 11.90% in the TD group (p<0.001) continued chemotherapy without showing any aggravation of present peripheral neuropathy.
Conclusion: The patients treated with LD showed less increase in the severity of peripheral neuropathy compared to those treated with TD. Significant difference also was observed between the drugs in the percentage of patients who continued the treatment without aggravation of peripheral neuropathy. However, other risk factors suggested in previous studies such as diabetes, decreased renal function or previous neurotoxic drug use did not show significant correlation with the aggravation of peripheral neuropathy.